Sharma East India Hosp Q1 Net Profit Drops 18.75%
Sharma East India Hospitals and Medical Research has reported a standalone net profit of ₹0.65 crore for the quarter ended June 2026, marking a decline of 18.75% compared to ₹0.80 crore in the same quarter last year. This drop in profitability comes amid rising operational costs and competitive pressures in the healthcare sector. The company's total income for the quarter stood at ₹11.42 crore, up from ₹10.95 crore in the corresponding period of the previous fiscal, reflecting a modest growth of 4.3%.
Despite the increase in revenue, the company's net profit margin contracted to 5.7% from 7.3% a year ago. This margin compression is attributed to higher employee costs and administrative expenses. The company's EBITDA for the quarter was ₹1.32 crore, down from ₹1.48 crore in Q1 FY26, indicating a 10.8% decline. Analysts say the hospital segment is facing pricing pressures and increased input costs, which are squeezing margins across the industry.
| Metric | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Net Profit (₹ crore) | 0.65 | 0.80 | -18.75% |
| Total Income (₹ crore) | 11.42 | 10.95 | +4.3% |
| EBITDA (₹ crore) | 1.32 | 1.48 | -10.8% |
| Net Profit Margin | 5.7% | 7.3% | -160 bps |
The company's earnings per share (EPS) for the quarter came in at ₹0.13, down from ₹0.16 in the year-ago period. The stock has been under pressure, trading near its 52-week low. Investors are concerned about the sustainability of earnings growth, especially with the company's debt levels remaining elevated. As of June 2026, the company's total debt stood at ₹24.5 crore, with a debt-to-equity ratio of 1.2, which is higher than the industry average.
"The healthcare sector is witnessing a slowdown in patient volumes due to seasonal factors and increased competition from new entrants. We expect margins to remain under pressure in the near term." - analysts say
Looking ahead, the management has indicated plans to focus on cost rationalization and expanding high-margin specialties such as cardiology and orthopedics. However, the near-term outlook remains cautious. The company's cash flow from operations for the quarter was ₹0.95 crore, down from ₹1.10 crore in Q1 FY26. With the festive season approaching, there is hope for a recovery in patient footfall, but analysts remain wary of rising input costs and regulatory changes.
For investors, the key monitorables will be the company's ability to control costs and improve bed occupancy rates. The stock's valuation, at a P/E of 18.5, appears expensive given the declining profitability. As the company navigates these challenges, stakeholders will be watching for signs of stabilization in the coming quarters. For more detailed analysis and updates, visit MarketToMoney.
To stay informed about the latest financial trends and investment opportunities, visit MarketToMoney.co.in for expert insights and real-time updates.